GlassScriptPhysician profile
Sherezade Khambatta
NPI 1790949741
$12,670.50
in general payments reported to CMS, 2019-2025
42 companies · $2,302 in 2025
The $2,302 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $817 · 2021: $1,822 · 2022: $1,840 · 2023: $2,784 · 2024: $2,131 · 2025: $2,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,216.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,731.44 | 2019-2025 | Pressurewire, Aveir, Cardiomems |
| Novartis Pharmaceuticals Corporation | $1,445.88 | 2019-2025 | |
| Boston Scientific Corporation | $943.12 | 2021-2025 | Watchman Access System, Emerge Push, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $752.71 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Janssen Pharmaceuticals, INC | $690.93 | 2019-2024 | Xarelto |
| Inari Medical, INC. | $657.59 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $598.20 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $562.68 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $507.56 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.73 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $419.60 | 2022-2025 | Onpattro, Amvuttra |
| Kestra Medical Technology Services, INC. | $389.29 | 2022-2025 | Assure Wcd |
| Pfizer INC. | $367.94 | 2021-2025 | |
| Cardiovascular Systems INC. | $337.14 | 2019-2021 | |
| Penumbra, INC. | $296.33 | 2023-2025 | Indigo System, Smart Coil |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $227.07 | 2020-2025 | Impella |
| United Therapeutics Corporation | $210.70 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Lexicon Pharmaceuticals, INC. | $186.88 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $185.23 | 2024-2025 | Wegovy |
| Philips North America LLC | $182.14 | 2022-2024 | (5044) Mcot |
| Amarin Pharma, INC. | $179.15 | 2019-2022 | |
| Scpharmaceuticals INC. | $172.44 | 2023-2025 | |
| Angiodynamics, INC. | $141.24 | 2023 | Alphavac |
| E.R. Squibb & Sons, L.L.C. | $129.01 | 2020-2025 | Camzyos, Eliquis |
| Bracco Diagnostics INC. | $124.96 | 2019 | |
| Cardiva Medical, INC. | $117.88 | 2023 | Cardiva Vascade 6/7f Vcs |
| Regeneron Healthcare Solutions, INC. | $113.37 | 2021-2022 | |
| Esperion Therapeutics, INC. | $100.59 | 2021-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $74.65 | 2022-2024 | Opsumit, Uptravi |
| Daiichi Sankyo INC. | $64.33 | 2023-2025 | Injectafer |
| Sanofi-Aventis U.S. LLC | $64.28 | 2019-2021 | |
| Medtronic, INC. | $63.52 | 2023-2024 | Venaseal |
| Astellas Pharma US INC | $36.49 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $36.34 | 2023 | Arcalyst |
| Heartflow, INC. | $24.51 | 2023 | Ffrct |
| Kiniksa Pharmaceuticals International, Plc | $19.97 | 2024 | Arcalyst |
| Cmp Pharma, INC. | $18.74 | 2023 | Carospir, Tadliq |
| Baxter Healthcare | $15.39 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic Vascular, INC. | $13.06 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2021 | |
| Edwards Lifesciences Corporation | $12.60 | 2019 | |
| Teleflex LLC | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherezade Khambatta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.